MCID: GLS001
MIFTS: 55

Gliosarcoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Gliosarcoma

MalaCards integrated aliases for Gliosarcoma:

Name: Gliosarcoma 12 50 56 52 42 14 69
Glioblastoma with Sarcomatous Component 12
Sarcomatous Glioblastoma 50

Characteristics:

Orphanet epidemiological data:

56
gliosarcoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3071
MeSH 42 D018316
NCIt 47 C3796
Orphanet 56 ORPHA251576
UMLS via Orphanet 70 C0206726
ICD10 via Orphanet 34 G71.9
UMLS 69 C0206726

Summaries for Gliosarcoma

NIH Rare Diseases : 50 this condition doesn't have a summary yet. please see our page(s) on glioblastoma.

MalaCards based summary : Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to giant cell glioblastoma and adult brainstem gliosarcoma, and has symptoms including headache and seizures. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and Downstream signaling events of B Cell Receptor (BCR). The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and t cells, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 72 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

Related Diseases for Gliosarcoma

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
id Related Disease Score Top Affiliating Genes
1 giant cell glioblastoma 29.0 EGFR GFAP IDH1 MGMT NES PPARG
2 adult brainstem gliosarcoma 11.9
3 omphalomesenteric cyst 11.1 GFAP MGMT
4 sella turcica neoplasm 11.1 GFAP NES
5 anaplastic plasmacytoma 11.1 GFAP NES
6 meningitis and encephalitis 11.1 GFAP S100B
7 pediatric ependymoma 11.0 GFAP NES S100B
8 mixed epithelial stromal tumour 11.0 GFAP NES S100B
9 hypoglossal nerve neoplasm 11.0 GFAP NES S100B
10 pancoast tumor 11.0 GFAP TP53
11 brain stem astrocytic neoplasm 11.0 GFAP TP53
12 hypogonadotropic hypogonadism-frontoparietal alopecia syndrome 10.9 GFAP IDH1
13 spleen angiosarcoma 10.9 GFAP S100B
14 pleural empyema 10.9 GFAP S100B TP53
15 brain glioma 10.9 GFAP NES TP53
16 immune-mediated encephalomyelitis 10.9 PTEN S100B
17 aggressive systemic mastocytosis 10.9 GFAP NES TP53
18 papillary glioneuronal tumor 10.9 GFAP IDH1 S100B
19 pediatric infratentorial ependymoma 10.9 EGFR TP53
20 chilaiditi syndrome 10.9 FGFR3 GFAP
21 renal pelvis urothelial papilloma 10.9 GFAP TP53
22 unilateral retinoblastoma 10.9 CCND3 RB1 TP53
23 pharynx cancer 10.9 CCND3 RB1 TP53
24 tendon sheath lipoma 10.9 GFAP TP53
25 skin hemangioma 10.9 GFAP NES TP53
26 ovarian mucinous cystadenofibroma 10.8 GFAP PTEN S100B
27 anaplastic oligodendroglioma 10.8 GFAP PTEN S100B
28 post-surgical hypoinsulinemia 10.8 CCND3 RB1 TP53
29 superior vena cava angiosarcoma 10.8 GFAP S100B TP53
30 breast fibrosarcoma 10.8 EGFR S100B TP53
31 neutrophil immunodeficiency syndrome 10.8 NES S100B TP53
32 hip subluxation 10.8 EGFR S100B TP53
33 hemangioma of liver 10.8 S100B TP53
34 cervical adenomyoma 10.8 GFAP NES S100B TP53
35 nemaline myopathy 10.8 FGFR1 IDH1
36 sternum cancer 10.8 GFAP NES S100B TP53
37 plasmalogens synthesis deficiency isolated 10.8 FGFR1 FGFR3
38 adenofibroma 10.8 GFAP IDH1 NES S100B
39 epidermolysa bullosa simplex with muscular dystrophy 10.8 EGFR GFAP MGMT NES S100B
40 peritoneal benign neoplasm 10.8 GFAP LZTR1 TP53
41 bannayan-riley-ruvalcaba syndrome 10.7 EGFR PTEN
42 iodine hypothyroidism 10.7 GFAP IDH1 TP53
43 mixed oligodendroglioma-astrocytoma 10.7 IDH1 TP53
44 mucinous ovarian cystadenoma 10.7 GFAP S100B
45 childhood medulloblastoma 10.7 GFAP IDH1 TP53
46 prostate transitional cell carcinoma 10.7 FGFR3 RB1 TP53
47 pilocytic astrocytoma of cerebellum 10.7 IDH1 TP53
48 osteopetrosis and infantile neuroaxonal dystrophy 10.7 FGFR1 FGFR3 NES S100B
49 congenital disorder of glycosylation, type if 10.7 IDH1 TP53
50 schwannoma of jugular foramen 10.7 GFAP IDH1 MGMT TP53

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to Gliosarcoma

Symptoms & Phenotypes for Gliosarcoma

UMLS symptoms related to Gliosarcoma:


headache, seizures

MGI Mouse Phenotypes related to Gliosarcoma:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.42 RB1 SNAI2 TACC3 TP53 CCND3 EGFR
2 homeostasis/metabolism MP:0005376 10.42 PTEN RB1 S100B SNAI2 TP53 CCND3
3 mortality/aging MP:0010768 10.38 TP53 CCND3 EGFR FGFR1 FGFR3 FREM2
4 hematopoietic system MP:0005397 10.37 CCND3 EGFR FGFR1 FGFR3 IDH1 LZTR1
5 behavior/neurological MP:0005386 10.36 CCND3 FGFR1 FGFR3 GFAP PPARG PTEN
6 immune system MP:0005387 10.35 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1
7 endocrine/exocrine gland MP:0005379 10.32 EGFR FGFR1 MGMT NFKBIA PPARG PTEN
8 cardiovascular system MP:0005385 10.31 FREM2 GFAP PPARG PTEN RB1 SNAI2
9 integument MP:0010771 10.26 EGFR FGFR1 FGFR3 FREM2 NFKBIA PPARG
10 embryo MP:0005380 10.24 EGFR FGFR1 FREM2 PPARG PTEN RB1
11 craniofacial MP:0005382 10.21 FGFR1 FGFR3 FREM2 RB1 SNAI2 TACC3
12 digestive/alimentary MP:0005381 10.2 EGFR FGFR1 FGFR3 GFAP PTEN RB1
13 normal MP:0002873 10.18 TACC3 TP53 CCND3 EGFR FGFR1 FGFR3
14 hearing/vestibular/ear MP:0005377 10.11 EGFR FGFR1 FGFR3 FREM2 PPARG RB1
15 limbs/digits/tail MP:0005371 10.11 EGFR FGFR1 FGFR3 FREM2 PTEN RB1
16 neoplasm MP:0002006 10.09 CCND3 EGFR FGFR3 MGMT PPARG PTEN
17 muscle MP:0005369 10.06 EGFR FGFR1 FREM2 GFAP PPARG PTEN
18 liver/biliary system MP:0005370 10.04 EGFR PPARG PTEN RB1 TACC3 TP53
19 renal/urinary system MP:0005367 9.92 EGFR FGFR1 FGFR3 FREM2 PPARG PTEN
20 reproductive system MP:0005389 9.91 EGFR FGFR1 FGFR3 FREM2 PPARG PTEN
21 pigmentation MP:0001186 9.85 EGFR FREM2 PTEN RB1 SNAI2 TP53
22 respiratory system MP:0005388 9.81 CCND3 EGFR FGFR3 FREM2 IDH1 MGMT
23 skeleton MP:0005390 9.7 EGFR FGFR1 FGFR3 FREM2 IDH1 PPARG
24 vision/eye MP:0005391 9.36 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP

Drugs & Therapeutics for Gliosarcoma

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 399)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
2
Lomustine Approved Phase 3,Phase 1 13010-47-4 3950
3
Procarbazine Approved Phase 3,Phase 1,Phase 2 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 1 3902-71-4 5585
5
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
6
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
9
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
12
Morphine Approved, Investigational Phase 3 57-27-2 5288826
13
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
14
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
15
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
16
Dopamine Approved Phase 3,Phase 1 51-61-6, 62-31-7 681
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
19
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
20 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
21
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
22 Dianhydrogalactitol Investigational Phase 3 23261-20-3
23 Alkylating Agents Phase 3,Phase 2,Phase 1
24 Dermatologic Agents Phase 3,Phase 1,Phase 2
25 Dihematoporphyrin Ether Phase 3,Phase 1
26 Ether Phase 3
27 Photosensitizing Agents Phase 3,Phase 2,Phase 1
28 Antirheumatic Agents Phase 3,Phase 1,Phase 2
29 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
30 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 3,Phase 1,Phase 2
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
33 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
34 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
35 Keratolytic Agents Phase 3,Phase 1,Phase 2
36 O(6)-benzylguanine Phase 3,Phase 2,Phase 1
37 Anesthetics Phase 3,Phase 1
38 Anesthetics, General Phase 3
39 Anesthetics, Inhalation Phase 3
40 Hematoporphyrin Derivative Phase 3
41 Hematoporphyrins Phase 3
42 Adjuvants, Anesthesia Phase 3
43 Analgesics Phase 3,Phase 2,Phase 1
44 Analgesics, Opioid Phase 3
45 Anesthetics, Intravenous Phase 3
46 Liver Extracts Phase 3,Phase 2,Phase 1
47 Narcotics Phase 3
48 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
49 Epoetin alfa Phase 3 113427-24-0
50 Cholinergic Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 464)

id Name Status NCT ID Phase Drugs
1 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
3 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
4 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
5 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
6 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
7 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
8 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
9 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
10 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
11 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
15 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
16 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib
17 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
18 Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Active, not recruiting NCT00884741 Phase 3 Placebo;Temozolomide pre-randomization;Temozolomide post-randomization
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
21 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
22 Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Unknown status NCT01124539 Phase 2 AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
23 Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma Unknown status NCT00936052 Phase 2
24 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
25 Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00486603 Phase 1, Phase 2 hydroxychloroquine;temozolomide
26 Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
27 Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme Unknown status NCT00003456 Phase 2 antineoplaston A10;antineoplaston AS2-1
28 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
29 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
30 Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
31 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
32 Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
33 Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme Unknown status NCT00003474 Phase 2 antineoplaston A10;antineoplaston AS2-1
34 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status NCT00003176 Phase 2 carmustine;temozolomide
35 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
36 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
37 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed NCT00525525 Phase 2 Bevacizumab;Tarceva;Temozolomide
38 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Completed NCT00612339 Phase 2 Avastin and Temozolomide
39 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
40 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed NCT00597402 Phase 2 Avastin;Temozolomide;Irinotecan
41 Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed NCT00402116 Phase 1, Phase 2 enzastaurin;temozolomide
42 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Completed NCT00187486 Phase 2 Tarceva;Temodar
43 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed NCT00433381 Phase 2 irinotecan hydrochloride;temozolomide
44 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00305864 Phase 1, Phase 2 temozolomide;motexafin gadolinium
45 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Completed NCT00979017 Phase 2 Avastin;Temozolomide;Irinotecan
46 Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00165477 Phase 2 lenalidomide
47 Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Completed NCT00883298 Phase 2 temozolomide and bevacizumab
48 AMG 102 and Avastin for Recurrent Malignant Glioma Completed NCT01113398 Phase 2 AMG 102;Avastin
49 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
50 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Completed NCT01856933 Phase 2 PSMA ADC

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Genetic Tests for Gliosarcoma

Anatomical Context for Gliosarcoma

MalaCards organs/tissues related to Gliosarcoma:

39
Brain, Bone, T Cells, Bone Marrow, Liver, Prostate, Spinal Cord

Publications for Gliosarcoma

Articles related to Gliosarcoma:

(show top 50) (show all 360)
id Title Authors Year
1
Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. ( 28621623 )
2017
2
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma. ( 28644110 )
2017
3
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted. ( 28812310 )
2017
4
Lateral ventricular gliosarcoma with attachment to septum pellucidum. ( 28413542 )
2017
5
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. ( 28261869 )
2017
6
Gliosarcoma in septuagenarians and octogenarians: What is the impact of adjuvant chemoradiation? ( 28756069 )
2017
7
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. ( 28408749 )
2017
8
Analysis of outcomes of multidisciplinary management of Gliosarcoma: a single centre study, 2000-2013. ( 28642179 )
2017
9
Photodithazine photodynamic effect on viability of 9L/lacZ gliosarcoma cell line. ( 28503718 )
2017
10
Glioblastoma recurrence, progression, and dissemination as a purely subdural gliosarcoma. ( 28290000 )
2017
11
Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24h in a rat 9L gliosarcoma model. ( 28887206 )
2017
12
Concurrent Gliosarcoma and Choroid Plexus Carcinoma in a Cow. ( 27899174 )
2016
13
Gliosarcoma with Primary Skull Base Invasion. ( 28053799 )
2016
14
An IDH1-mutated primary gliosarcoma: case report. ( 27153165 )
2016
15
Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging. ( 26802746 )
2016
16
Metastatic Gliosarcoma: Cytopathologic Characteristics with Histopathologic Correlations. ( 27584833 )
2016
17
Post-Treatment Gliosarcoma Extension into the Pterygomaxillary Fossa: Literature Review and Case Report. ( 27699141 )
2016
18
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. ( 27169763 )
2016
19
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. ( 26725096 )
2016
20
Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( 27025857 )
2016
21
Primary Multifocal Gliosarcoma of the Spinal Cord. ( 27134708 )
2016
22
Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. ( 27672648 )
2016
23
Dural and osteolytic sarcomatoid relapse of a secondary gliosarcoma with tryptase immunoreactivity. ( 26784965 )
2016
24
Temporal Lobe Gliosarcoma After Gamma Knife Radiosurgery for Vestibular Schwannoma. ( 27309712 )
2016
25
Gliosarcoma with a primitive neuroectodermal tumour component. ( 27772848 )
2016
26
Gliosarcoma in the Cerebellopontine Angle with Rapid Tumor Growth and Intratumoral Hemorrhage. ( 27338213 )
2016
27
Gliosarcoma with smooth muscle cell differentiation: a case report. ( 27704522 )
2016
28
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
29
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )
2016
30
A Stable Secondary Gliosarcoma with Extensive Systemic Metastases: A Case Report. ( 27867925 )
2016
31
Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient. ( 27523101 )
2016
32
Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma. ( 27130721 )
2016
33
Gliosarcomas lack BRAF(V600E) mutation, but a subset exhibit I^-catenin nuclear localization. ( 26932501 )
2016
34
Primary Gliosarcoma of the Optic Nerve: A Unique Adult Optic Pathway Glioma. ( 27792048 )
2016
35
Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line. ( 25539862 )
2015
36
Gliosarcoma with neuroaxis metastases. ( 26621904 )
2015
37
Long-term survival in gliosarcoma with radiation-induced meningeal sarcomas: Case report and molecular features. ( 26458625 )
2015
38
Gliosarcoma with leiomyomatous differentiation: A case report with an emphasis on histogenesis. ( 26881542 )
2015
39
Therapeutic management of gliosarcoma in the temozolomide era. ( 25905568 )
2015
40
Gliosarcoma with primitive neuroectodermal, osseous, cartilage and adipocyte differentiation: a case report. ( 25973108 )
2015
41
Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience. ( 25839013 )
2015
42
Assessing Amide Proton Transfer (APT) MRI Contrast Origins in 9A L Gliosarcoma in the Rat Brain Using Proteomic Analysis. ( 25622812 )
2015
43
FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment. ( 26279698 )
2015
44
Primary Cerebellar Gliosarcoma with Extracranial Metastases: An Orphan Differential Diagnosis. ( 26239018 )
2015
45
Giant parietal lobe infantile gliosarcoma in a 5-year-old child. ( 26167224 )
2015
46
Genetic alterations in gliosarcoma and giant cell glioblastoma. ( 26443480 )
2015
47
Cerebral gliosarcoma: Analysis of 16 patients and review of literature. ( 26396606 )
2015
48
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide. ( 26438548 )
2015
49
Brachium Pontis Gliosarcoma With Well-Differentiated Cartilaginous Tissue: A Case Report. ( 26496287 )
2015
50
Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases. ( 26960490 )
2015

Variations for Gliosarcoma

Cosmic variations for Gliosarcoma:

9 (show all 11)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10893 TP53 central nervous system,brain,glioma,gliosarcoma c.824G>A p.C275Y 5
2 COSM10648 TP53 central nervous system,brain,glioma,gliosarcoma c.524G>A p.R175H 5
3 COSM5308 PTEN central nervous system,brain,glioma,gliosarcoma c.565A>T p.R189* 5
4 COSM5154 PTEN central nervous system,brain,glioma,gliosarcoma c.697C>T p.R233* 5
5 COSM5191 PTEN central nervous system,brain,glioma,gliosarcoma c.198G>T p.K66N 5
6 COSM5152 PTEN central nervous system,brain,glioma,gliosarcoma c.388C>T p.R130* 5
7 COSM5033 PTEN central nervous system,brain,glioma,gliosarcoma c.389G>A p.R130Q 5
8 COSM5123 PTEN central nervous system,brain,glioma,gliosarcoma c.395G>A p.G132D 5
9 COSM22413 PDGFRA central nervous system,brain,glioma,gliosarcoma c.2472C>T p.V824V 5
10 COSM564 NRAS central nervous system,brain,glioma,gliosarcoma c.35G>A p.G12D 5
11 COSM476 BRAF central nervous system,brain,glioma,gliosarcoma c.1799T>A p.V600E 5

Expression for Gliosarcoma

Search GEO for disease gene expression data for Gliosarcoma.

Pathways for Gliosarcoma

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CCND3 EGFR FGFR1 FGFR3 GFAP NFKBIA
2
Show member pathways
12.63 EGFR FGFR1 FGFR3 NFKBIA PTEN TP53
3 12.56 CCND3 EGFR FGFR1 FGFR3 PTEN RB1
4 12.43 CCND3 MGMT RB1 TACC3 TP53
5
Show member pathways
12.42 EGFR FGFR1 FGFR3 PTEN TP53
6
Show member pathways
12.39 EGFR FGFR1 FGFR3 NFKBIA PPARG PTEN
7 12.36 CCND3 NFKBIA RB1 TP53
8
Show member pathways
12.36 EGFR FGFR1 FGFR3 NFKBIA TP53
9
Show member pathways
12.32 CCND3 NFKBIA PTEN TP53
10
Show member pathways
12.3 CCND3 PTEN RB1 TP53
11 12.23 CCND3 NFKBIA RB1 TP53
12
Show member pathways
12.17 EGFR FGFR1 FGFR3 PTEN
13 12.15 EGFR FGFR1 FGFR3 NFKBIA PPARG PTEN
14 12.09 EGFR PTEN RB1 TP53
15 12.01 CCND3 MGMT PTEN TP53
16 11.93 EGFR GFAP RB1 TP53
17 11.92 EGFR PTEN RB1 SNAI2 TP53
18
Show member pathways
11.91 CCND3 EGFR FGFR1 FGFR3 PTEN RB1
19 11.83 FGFR1 FGFR3 GFAP SNAI2
20 11.81 EGFR MGMT PTEN RB1 TP53
21 11.79 EGFR PTEN RB1
22 11.77 CCND3 RB1 TP53
23 11.72 NFKBIA PTEN RB1 TP53
24 11.66 EGFR FGFR1 SNAI2
25 11.62 EGFR FGFR3 RB1 TP53
26 11.56 FGFR1 FGFR3 GFAP NES S100B
27 11.49 EGFR RB1 TP53
28 11.44 PTEN RB1 TP53
29 11.42 EGFR FGFR1 FGFR3
30 11.4 CCND3 NFKBIA TP53
31 11.11 NFKBIA TACC1 TACC3 TP53
32 10.91 EGFR FGFR1 FGFR3 IDH1 PTEN TP53

GO Terms for Gliosarcoma

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 EGFR FGFR1 FGFR3 PTEN S100B
2 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.97 CCND3 FGFR1 PPARG RB1 SNAI2 TP53
3 cell cycle GO:0007049 9.91 CCND3 RB1 SEPT14 TACC1 TACC3 TP53
4 cell division GO:0051301 9.85 CCND3 RB1 SEPT14 TACC1 TACC3
5 regulation of cell proliferation GO:0042127 9.84 CCND3 EGFR FGFR1 NFKBIA
6 negative regulation of apoptotic process GO:0043066 9.8 EGFR MGMT NFKBIA PTEN SNAI2 TP53
7 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.72 EGFR FGFR1 FGFR3
8 cell proliferation GO:0008283 9.63 EGFR PTEN S100B TACC1 TACC3 TP53
9 learning or memory GO:0007611 9.58 EGFR PTEN S100B
10 white fat cell differentiation GO:0050872 9.57 PPARG SNAI2
11 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.56 NFKBIA PPARG
12 negative regulation of telomerase activity GO:0051974 9.52 PPARG TP53
13 salivary gland morphogenesis GO:0007435 9.51 EGFR FGFR1
14 positive regulation of phospholipase activity GO:0010518 9.48 FGFR1 FGFR3
15 cellular response to ionizing radiation GO:0071479 9.43 MGMT SNAI2 TP53
16 long-term synaptic potentiation GO:0060291 9.37 PTEN S100B
17 response to organic cyclic compound GO:0014070 9.35 EGFR IDH1 MGMT PPARG PTEN
18 phosphatidylinositol-mediated signaling GO:0048015 9.02 EGFR FGFR1 FGFR3 PTEN TP53

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.54 EGFR PPARG TP53
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR FGFR1 FGFR3
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 EGFR FGFR1 FGFR3
4 enzyme binding GO:0019899 9.43 EGFR NFKBIA PPARG PTEN RB1 TP53
5 identical protein binding GO:0042802 9.28 EGFR FGFR1 GFAP NFKBIA PPARG PTEN
6 fibroblast growth factor-activated receptor activity GO:0005007 9.16 FGFR1 FGFR3

Sources for Gliosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....